AbbVie (ABBV) Lands Phase 3 Migraine Study Win In The Lancet Neurology

What happened: AbbVie (NYSE: ABBV) reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention, published in The Lancet Neurology. QULIPTA showed superior efficacy and tolerability versus topiramate. Key numbers: 545 patients, 12 countries. Why it matters: The data reinforce QULIPTA's profile within AbbVie's neuroscience portfolio, which the content frames as needing to help offset pressure from Humira and Imbruvica. Next markers cited are quarterly guidance commentary and 2027 and 2028 segment revenue breakdowns. Market: -2.2% today ($288.70), +28.0% YTD, 0.4x vol — as of 15:33 UTC Verified: Q3_2026 (Oct 30) EPS $3.82 vs $3.77 est, +1.3% beat; next print ~Jan 29

AbbVie (NYSE: ABBV) reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention, published in The Lancet Neurology. QULIPTA showed superior efficacy and tolerability versus topiramate.

The data reinforce QULIPTA's profile within AbbVie's neuroscience portfolio, which the content frames as needing to help offset pressure from Humira and Imbruvica. Next markers cited are quarterly guidance commentary and 2027 and 2028 segment revenue breakdowns. Market: -2.2% today ($288.70), +28.0% YTD, 0.4x vol — as of 15:33 UTC Verified: Q3_2026 (Oct 30) EPS $3.82 vs $3.77 est, +1.3% beat; next print ~Jan 29